Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: March 30, 2023

Details for Patent: 9,326,945

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $100
Remove trial restrictions

Which drugs does patent 9,326,945 protect, and when does it expire?

Patent 9,326,945 protects ELIQUIS and is included in one NDA.

This patent has ninety-five patent family members in twenty-nine countries.

Summary for Patent: 9,326,945
Title:Apixaban formulations
Abstract: Compositions comprising crystalline apixaban particles having a D.sub.90 equal to or less than 89 .mu.m, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.
Inventor(s): Patel; Jatin (West Windsor, NJ), Frost; Charles (Yardley, PA), Jia; Jingpin (Belle Mead, NJ), Vemavarapu; Chandra (Hillsborough, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ) Pfizer Inc. (New York, NY)
Application Number:13/579,796
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,326,945
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form;

Drugs Protected by US Patent 9,326,945

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 AB RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-002 Dec 28, 2012 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,326,945

PCT Information
PCT FiledFebruary 24, 2011PCT Application Number:PCT/US2011/025994
PCT Publication Date:September 01, 2011PCT Publication Number: WO2011/106478

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.